DRTS - Cancer Goes Bye Bye / Portfolio Goes High High
DRTS's radium-224 alpha-particle cancer therapy works on multiple solid tumor types regardless of genetic signature, offering superior outcomes compared to conventional oncology treatments. Early trial results show strong efficacy (100% local disease control in pancreatic, high complete response in glioblastoma, FDA breakthrough designation), with the author projecting significant value creation as regulatory and logistical challenges are solved.